Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. - Wikidata - wikimedia - TriplyDB

Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL.

Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL.

http://www.wikidata.org/entity/Q33730717

about

Cancer immunotherapy: the beginning of the end of cancer?shRNA-armed conditionally replicative adenoviruses: a promising approach for cancer therapy To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy Genetic, immunological, and pharmacological strategies to generate improved oncolytic viruses 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity Oncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpoints Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.Gene carriers and transfection systems used in the recombination of dendritic cells for effective cancer immunotherapy.Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF.Immune cells: more than simple carriers for systemic delivery of oncolytic viruses.Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα.Negative regulation-resistant p53 variant enhances oncolytic adenoviral gene therapy.Virotherapy, gene transfer and immunostimulatory monoclonal antibodies.Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model.Oncolytic adenovirus expressing IL-23 and p35 elicits IFN-γ- and TNF-α-co-producing T cell-mediated antitumor immunity.Dendritic cells serve as a "Trojan horse" for oncolytic adenovirus delivery in the treatment of mouse prostate cancer Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model.Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy.New approaches to the development of adenoviral dendritic cell vaccines in melanoma.Recent advances in oncolytic virus design.T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy.Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers.Evolution of oncolytic viruses: novel strategies for cancer treatment.Arming oncolytic viruses to leverage antitumor immunity.Fighting Cancer with Mathematics and Viruses.Evaluating optimal therapy robustness by virtual expansion of a sample population, with a case study in cancer immunotherapy.Human adenovirus type 5 vectors deleted of early region 1 (E1) undergo limited expression of early replicative E2 proteins and DNA replication in non-permissive cells.Evolving lessons on nanomaterial-coated viral vectors for local and systemic gene therapy.Oncolytic Immunotherapy for Treatment of Cancer.Oncolytic viruses-immunotherapeutics on the rise.Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers.Sustained local delivery of oncolytic short hairpin RNA adenoviruses for treatment of head and neck cancer.Local sustained delivery of oncolytic adenovirus with injectable alginate gel for cancer virotherapy.Long-term proliferation of functional human NK cells, with conversion of CD56(dim) NK cells to a CD56 (bright) phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12.Strengthening of antitumor immune memory and prevention of thymic atrophy mediated by adenovirus expressing IL-12 and GM-CSF.Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.Efficacy of combining ING4 and TRAIL genes in cancer-targeting gene virotherapy strategy: First evidence in preclinical hepatocellular carcinoma.Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma.New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy.

P2860

Q26752277-373AD0AC-6BC1-4DEA-8772-9EFDF20E1023 Q26765364-386B2269-43B7-491E-B5C2-46CB2F5435E2 Q26767212-39D4F5EE-A96D-4E22-80EB-FBE1626419BB Q26774345-356B2EB2-3646-439E-923A-B8E39CF173B2 Q26859879-3C9D65CF-13B8-4718-B6FB-E904598607A3 Q27012963-A0FC41BC-45B0-45C8-8528-E1D1B887B105 Q28083515-B79A603D-68E7-4879-838A-3CD4AE9E3387 Q33906116-F5139147-54BF-4E88-8985-1B439A0F8B41 Q34443707-017300E6-C351-4364-BD6C-0AE9ACC4E77A Q35144428-3833C56B-FA7B-4478-A6D1-5ED50A705252 Q35162284-2DF38F4F-6529-40EA-A595-7762BD5FB970 Q35204881-C6C85546-2F0E-4839-ADD9-8208FA8B4653 Q36084467-B9C1E2FD-2AB2-44A9-ACC1-2AD1A54E6A6B Q36456487-F6C4BA4A-2A8B-4548-8E99-7850CA76A73C Q36879787-1457F01C-E9B1-418B-8CCE-11DB19BC4438 Q36981396-C3D26F0B-ADBB-4F61-AD38-97361E50C7EA Q37151620-32918D7C-CE05-4F84-96CE-F824B04DBB02 Q37706248-A09956DC-5482-4E38-9EA2-8F379EA59C4B Q37709052-84D103BB-5C4D-4938-8F73-F0D96258FBB3 Q37820489-C8D3ACB8-F750-404C-9984-972959BAFB6A Q37865172-DB2AC5BA-154A-4DDE-AB1E-3B4F83AA2E5E Q37948129-1AC00993-5723-4DB3-9403-931C19474BA4 Q38073096-907DEC65-F55C-4A0C-A659-EBF6322F1B37 Q38159802-4A2577DE-529A-43DA-BF19-EE704148A6D4 Q38470166-CB7BE68D-9E16-4A4F-841D-A9538AE500D0 Q38612646-F022E4ED-9E15-4101-9EEF-0525CFB7D814 Q38674852-D3B3690A-4872-4559-ABB0-4E179ACADFF8 Q38682348-F67AA43C-C35D-4D8F-A2FB-60B672C74006 Q38848060-016F097C-598D-4B32-BD8C-03009FE3FA71 Q38848223-398E139F-8E2D-4841-8135-9D932BCA23FB Q38919107-5D6CE868-BA17-4178-B951-E19E4BB0C770 Q38974499-A68E6B41-D58C-4652-A44B-F746AE4BF823 Q38981481-32A3B914-7313-42E0-A27D-B272A5C8BDFC Q39178068-6FDDF26D-96E7-4FDC-A146-F0BBD0437D40 Q39453997-FE008F2C-9432-425B-8CBE-D8EB0F922BD8 Q39459281-E21AF5DA-968C-4FC2-87D6-1F0ACF7B44D0 Q45862822-68A547EF-76B2-4861-8398-280B431FCFCE Q45872155-747B8DF5-C859-431D-B9CA-3FAD0F964552 Q47141309-458E5B2A-3642-4A1B-A429-E30C013F6A0C Q50056861-3B4695C0-ABC6-4CD8-A51F-AECA34827A10

P2860

Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL.

http://www.wikidata.org/entity/Q33730717

description

2009 nî lūn-bûn

@nan

2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Therapeutic and tumor-specific ...... s expressing IL-12 and 4-1BBL.

@ast

Therapeutic and tumor-specific ...... s expressing IL-12 and 4-1BBL.

@en

type

label

Therapeutic and tumor-specific ...... s expressing IL-12 and 4-1BBL.

@ast

Therapeutic and tumor-specific ...... s expressing IL-12 and 4-1BBL.

@en

prefLabel

Therapeutic and tumor-specific ...... s expressing IL-12 and 4-1BBL.

@ast

Therapeutic and tumor-specific ...... s expressing IL-12 and 4-1BBL.

@en

P1433

Q33730717-55C86B11-2CBE-4DF8-B9FA-82D8EAB12468

P1476

Q33730717-B26BBEF2-996A-4C74-8343-49B43CA61E27

P2093

Q33730717-1CD13E9B-50F7-4A0B-AF4C-265520608498

Q33730717-616F69CA-E88D-4009-9D01-C2F1F5C27B54

Q33730717-690387A4-1597-40E8-9F46-CB54A7846ED3

Q33730717-A620EC9A-4A35-43D7-8153-4CD20AD74822

Q33730717-AA9534AA-8AF7-4975-B8E0-C3E13A526368

Q33730717-C1E13E80-143A-41A3-9455-31265C59DDA5

Q33730717-C997B9A7-5B38-4DF6-884C-83C74D43E74C

P2860

Q33730717-0D3CF613-277A-4A4A-B7AD-5AD6EDD6267E

Q33730717-0E99681E-A245-4D7D-8779-B6718DC135BD

Q33730717-13518CF2-9D64-486E-B827-B1954F05F083

Q33730717-2B33FA5F-ED9B-4087-9E1E-A9BD038136BD

Q33730717-328BF9EC-8F59-421B-9C55-502F2BCD48CE

Q33730717-33EDE7AC-0952-41DE-844F-E1C59EB6D41B

Q33730717-36BB5FB9-49B9-419A-9D33-DCCAB79C0BAD

Q33730717-3F6A8585-BE27-4595-8ED2-A1AFCDBED773

Q33730717-4842D1FA-21A8-4062-AB48-85CBDAF992BC

Q33730717-497B053D-B7C2-4B7C-AE3F-7BEA1FB4F3CF

P304

Q33730717-85940A26-858F-473D-A81C-561E1CF977D5

P31

Q33730717-CE5744B6-6473-47AF-BE6C-D448DCFC1254

P356

Q33730717-440B5886-894A-41F4-A3DF-CB9AD6A84DA9

P433

Q33730717-82841754-A517-452A-82F3-B6B38ECA5C89

P478

Q33730717-9BA86471-FDD4-4786-AC9D-31F3CF83CF19

P50

Q33730717-FC318D7E-8210-42D1-A295-9EEFCD9D8F75

P577

Q33730717-485E2395-75FC-45A1-9406-ED2D7A666B66

P5875

Q33730717-27490F5C-FFC8-4C97-B085-C9BCA004220A

P698

Q33730717-F65A2793-512D-43CE-9BD6-E269EBF61B4B

P921

Q33730717-00C39DC1-7F3E-48EF-BDC4-4205585A3073

Q33730717-F0A3865D-4EE2-4ADD-B679-67B62BE22C0A

P932

Q33730717-1D40A5FF-9A14-43F5-A88F-0AA13F1883C2

P356

P1433

Molecular Therapy

P1476

Therapeutic and tumor-specific ...... us expressing IL-12 and 4-1BBL

@en

P2093

Hoguen Kim

http://www.w3.org/2001/XMLSchema#string

Il-Kyu Choi

http://www.w3.org/2001/XMLSchema#string

Jing-Hua Huang

http://www.w3.org/2001/XMLSchema#string

Joo-Hang Kim

http://www.w3.org/2001/XMLSchema#string

Kyung-Ju Choi

http://www.w3.org/2001/XMLSchema#string

Min-Geol Lee

http://www.w3.org/2001/XMLSchema#string

Song-Nan Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Interleukin 12-dependent interferon gamma production by CD8alpha+ lymphoid dendritic cells

Dendritic cells are defective in breast cancer patients: a potential role for polyamine in this immunodeficiency

TNF/TNFR family members in costimulation of T cell responses

Immunosuppressive networks in the tumour environment and their therapeutic relevance

Dendritic cells in cancer immunotherapy.

Replicative adenoviruses for cancer therapy.

Cancer gene therapy: scientific basis.

Interleukin-12 in anti-tumor immunity and immunotherapy.

Dendritic cells: a journey from laboratory to clinic.

Mechanism of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids.

P304

264-274

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2009.205

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-09-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26797437

http://www.w3.org/2001/XMLSchema#string

P698

19738604

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

2839296

http://www.w3.org/2001/XMLSchema#string